## **Special Issue**

# Next-Generation Contrast Agents for Medical Imaging

## Message from the Guest Editors

The early detection of a number of pathologies, such as coronary, neurovascular, and tumor diseases, has been one of the main strategies adopted in clinical practice to reduce mortality. The development of imaging technologies has made an important contribution in this direction. Currently, the research in this area focuses on the development of contrast agents with high sensitivity and specificity. Vectorization with specific biomarkers has been one of the most commonly used strategies, presenting very promising results. This Special Issue, entitled "Next-Generation Contrast Agents for Medical Imaging", invites researchers to contribute with original research or review papers related to the design/development of contrast agents for Imaging. This Special Issue intends to summarize the state of the art and the latest findings in the field of contrast agents', as well as to propose future directions for this area. The contributions may include the synthesis of targeted contrast agents, biological and pharmacological characterization, the evaluation of imaging techniques and in vitro and in vivo studies.

#### **Guest Editors**

Dr. Sara Pinto

Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal

Dr. Rafael Aroso

University of Coimbra, Coimbra Chemistry Centre, Department of Chemistry, Rua Larga, 3004-535 Coimbra, Portugal

## Deadline for manuscript submissions

closed (20 December 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/141220

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

